Chandra Belani, MD oncologists overviews the latest standard of care for non-small-cell-lung-cancer NSCLC
Related Post:
Pemetrexed
Dr. Chandra P. Belani reports that maintenance therapy with pemetrexed significantly improves overall survival in advanced non-small cell lung cancer. Damian McNamara of the Global ...
Mesothelioma Drug Alimta Helps Lung Cancer Patients
Eli Lilly and Company has recently received its fourth approval from the Food and Drug Administration (FDA) for its drug Alimta (pemetrexed), a chemotherapy drug ...
Mesothelioma and Asbestos Lung Cancer Testing: Rosetta Genomics Receives Good Results from Johns Hopkins University
In a recent study conducted with the Department of Pathology at Johns Hopkins University School of Medicine, Rosetta Genomic’s miRview(TM) squamous test demonstrated high accuracy ...
Mesothelioma Chemotherapy Drug Alimta Continues to Benefit Mesothelioma Patients
Recent clinical trials in trimodality therapy continue to prove the efficacy of Alimta (pemetrexed) when combined with cisplatin in mesothelioma patients. Dating back to 2004, ...
GRACEcast-004_Lung-Cancer_Antiangiogenesis in First Line NSCLC
cancergrace.org This presentation by medical oncologist and lung cancer expert Dr. Jack West introduces the concept of angiogenesis, with a focus on the combination of ...
Tags: alimta, avastin, bevacizumab, erlotinib, premetrxed, tarceva